Search results
Showing 991 to 1005 of 1308 results for social care
NICE has developed a medtech innovation briefing (MIB) on Fungitell for antifungal treatment stratification .
In development Reference number: GID-TA11449 Expected publication date: TBC
Evidence-based recommendations on vorasidenib (Voranigo) for treating grade 2 astrocytoma or oligodendroglioma in people 12 years and over.
Evidence-based recommendations on Sleepio to treat insomnia and insomnia symptoms.
Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.
Evidence summaries: new medicines – Integrated process statement (PMG11)
This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)
Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults.
Show all sections
Agenda and papers of the NICE public board meeting on 19 March 2025
Agenda and papers of the NICE public board meeting on 22 September
Agenda and papers of the NICE public board meeting on 20 May 2025
Agenda and papers of the NICE public board meeting on 22 July 2025
Agenda and papers of the NICE public board meeting on 18 September 2025
Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.
In development Reference number: GID-TA10261 Expected publication date: TBC
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease [TSID11941]
In development Reference number: GID-TA11481 Expected publication date: TBC